LIPELLA PHARMACEUTICALS INC.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Emerging growth company
State of Incorporation
DE
Business Address
400 N LEXINGTON ST, PITTSBURGH, PA, 15208
Mailing Address
400 N LEXINGTON ST, PITTSBURGH, PA, 15208
Phone
412-901-0315
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2024
$754K
Total Liabilities
$-4.79
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 31, 2026 | View on SEC |
| 8-K Current report of material events | February 4, 2026 | View on SEC |
| 10-Q Quarterly financial report | November 14, 2025 | View on SEC |
| 8-K Current report of material events | October 21, 2025 | View on SEC |
| 8-K Current report of material events | October 9, 2025 | View on SEC |
| 8-K Current report of material events | September 18, 2025 | View on SEC |
| 10-Q Quarterly financial report | August 14, 2025 | View on SEC |
| 8-K Current report of material events | June 25, 2025 | View on SEC |
| 8-K Current report of material events | June 20, 2025 | View on SEC |
| 8-K Current report of material events | June 16, 2025 | View on SEC |
Material Events
8-K
Bankruptcy
March 31, 2026
High Impact
- Initiation of Chapter 11 bankruptcy reorganization
- Planned '363 sale' of core drug delivery assets and clinical candidates LP-10 and LP-310
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.